title: Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.
abstract: Ovarian cancer is one of the gynecologic cancers with the highest mortality, wherein vascular endothelial growth factor (VEGF) is involved in regulating tumor vascularization, growth, migration, and invasion. VEGF-mediated angiogenesis in tumors has been targeted in various cancer treatments, and anti-VEGF therapy has been used clinically for treatment of several types of cancer. Paclitaxel is a natural antitumor agent in the standard front-line treatment that has significant efficiency to treat advanced cancers, including ovarian cancer. Although platinum/paclitaxel-based chemotherapy has good response rates, most patients eventually relapse because the disease develops drug resistance. We aim to review the recent advances in paclitaxel treatment of ovarian cancer via antiangiogenesis. Single-agent therapy may be used in selected cases of ovarian cancer. However, to prevent drug resistance, drug combinations should be identified for optimal effectiveness and existing therapies should be improved.
authors.affiliation: Department of Medical Oncology, Beijing Hospital, National Center of Gerontology Beijing 100730, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Ai
authors.affiliation: Department of Medical Oncology, Beijing Hospital, National Center of Gerontology Beijing 100730, China.
authors.forename: Zhixin
authors.initials: Z
authors.lastname: Bie
authors.affiliation: Department of Medical Oncology, Beijing Hospital, National Center of Gerontology Beijing 100730, China.
authors.forename: Shuai
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Institute of Microcirculation, PUMC&CAMS Beijing 100005, China.
authors.forename: Ailing
authors.initials: A
authors.lastname: Li
keywords: Paclitaxel; angiogenesis; ovarian cancer; vascular endothelial growth factor (VEGF)